Donald Trump’s new drug pricing website credits the president for saving American patients money. That in turn may influence global prices. But Chirantan Chatterjee argues that TrumpRx is largely performative and political, and that if countries want cheaper drugs then procurement reform, generics and supply chains matter more than portals.
Few political promises resonate more strongly than cheaper medicines. This linkage between politics and drug prices remains as true today as it did two decades ago when Sarah Ellison and Catherine Wolfram, economists at MIT and UC Berkeley, reported how pharmaceutical price co-ordination occurred under political pressure.
They reported how firms based on their vulnerability to future price regulation, took various actions to forestall regulation, most notably co-ordinating on a specific percentage price increase during 1993. These efforts remain salient even today in 2026 with rising drug costs becoming a visible lightning rod for wider cost-of-living pressures in our post pandemic inflationary world.
Bio-pharmaceutical innovation is laced with high complexity and uncertainty, cost of failure and long-time taken for discovery. This is even more so in the current era of biological large molecule drugs instead of chemistry based small molecule compounds. Hence, without incentives for innovation, firms wouldn’t risk engaging in drug discovery that for an average new pill can incur research and development (R&D) expenditure of about $2 billion with a success rate of 1 in 10,000 compounds, and it taking 10-12 years for a new drug to hit the market. It is for these reasons, innovator firms argue they need apriori market protection like patents, which make drug prices prohibitive. It is also for this reason that for affordability concerns around the world, governments regularly intervene to solve this tension between access and innovation with low-hanging tools like price controls.
So, while drug pricing merits interventions, many recent political responses focus more on performativism than on changing structurally how pharmaceutical markets function or how market power in drug pricing prevail. The launch of America’s new drug pricing portal, TrumpRx, reminds us of this again. It also raises a foundational question: are governments structurally reforming pharmaceutical markets, or simply rebranding prices?
Is TrumpRx really “rewriting the script”?
TrumpRx (“Rx” is a widely used shorthand for prescriptions) aggregates manufacturer discounts and selected offers on prescription medicines. These are then marketed as Donald Trump himself delivering rapid savings for American patients. The messaging is not subtle: “Thanks to President Trump, the days of Big Pharma price-gouging are over.” But they are politically powerful: government action will lead to lower prices, salient even more so in a mid-term election year with domestic pressures on cost of living.
Yet early reporting suggests several medicines included already have cheaper generic alternatives available through insurance or pharmacy discount channels, meaning savings may be less dramatic than claimed. For medicines such as insulin or GLP-1 weight-loss drugs like semaglutide (sold as Ozempic or Wegovy), list prices often exceed $1,000 per month in America, while many patients already pay less thanks to negotiated insurance prices or generics. It is also now reported that out of 43 brand name drugs, 20 have generic versions available from other options like Mark Cuban’s Cost Plus Drugs (the TrumpRX website doesn’t include generic drugs).
No wonder firms like Novo Nordisk are under pricing pressures in America and their shareholders have responded adversely particularly when American peer competing firm Eli Lilly has struck voluntary pricing deals to lower prices with the government. This looks like a government versus industry pricing game theoretic problem which could play out in lowering in aggregate prices. But the other dynamic of a portal launch with political fanfare raises a question that health economist colleagues across Europe, India and China now ask me privately: why this initiative, and why now?
TrumpRx matters beyond America
We will answer that. But while at it, let us also recognise that TrumpRx matters beyond America, because pharmaceutical markets are globally interconnected even today in a de-globalising world. American prices often influence global pricing negotiations shaping reimbursement decisions across the European Union and other advanced economies. Research by the Organisation for Economic Co-operation and Development (OECD) shows that international price referencing means American price changes can spill over into EU and British procurement negotiations and impact conversations on tariffs from 2025. If TrumpRx reduces effective American prices, ripple effects may reshape procurement dynamics abroad.
Prior work in pharmaceutical economics consistently shows that durable affordability emerges when policy changes alter incentives rather than merely through tokenistic discounts. Cross-country evidence reviewed by health economists at the OECD demonstrates that savings persist when competition and procurement frameworks shift market bargaining power rather than when discounts remain confined to isolated channels. In my own research with Samarth Gupta (IIM Calcutta), evidence from India provides particularly useful insight into how markets respond to government intervention.
We studied how private pharmacies reacted when governments introduced public medicine outlets selling discounted generics. The results showed competition sometimes works, but not always, and is conditioned by consumer behaviour and market structure. Where consumers trusted generics, private sellers reduced prices; but where consumers were more concerned about quality like for cancer drugs, firms segmented markets instead.
These dynamics could now also matter globally. Downward American prices could strengthen negotiating positions for Britain and EU governments already managing rising pharmaceutical expenditure. But lower expected returns for drug innovator companies also raise risks for innovation incentives. Pharmaceutical research and development remains concentrated in markets where firms can recover high development costs (like America), a pattern widely documented in economic studies of pharmaceutical innovation incentives. Significant price compression risks slowing investment in costly biologics and next-generation therapies.
TrumpRx’s pressure on prices could also create new opportunities for manufacturers in emerging economies. Indian generic firms and their peers like Cipla or Dr. Reddy’s Laboratories, are now expanding into biosimilars, lower-cost versions of biologic drugs, supported by growing regulatory and manufacturing capabilities. Global shifts toward cheaper alternatives could accelerate biosimilar adoption, strengthening imitator firm’s role in global pharmaceutical supply chains. Pricing politics in America with TrumpRx could thus reshape global production incentives as well.
The broader lesson is that medicines markets remain governed by incentives, regulation, procurement systems and consumer trust and not just headline portal announcements – especially if they are not improving affordability of drugs substantively on the margin. Brazil’s Farmácia Popular programme, for instance, expanded medicine access via subsidised pharmacy networks, improving affordability while raising debates about fiscal sustainability and targeting. In Europe, governments rely more heavily on procurement negotiation frameworks than retail-facing discount initiatives. Both offer instances of going beyond the symbolism that TrumpRx risks landing into.
What does this mean for policymakers?
So, if all of this is true, why do such pharmaceutical pricing policies persist? Political incentives answer the question clearly and also provide a cue to the “why now?” question raised earlier. Health expenditures are emotionally and electorally salient. Governments face pressure to demonstrate action quickly, and visible price initiatives produce immediate political returns even if structural outcomes remain uncertain. OECD reviews repeatedly note that procurement reform and competition policy deliver savings slowly, while announcements deliver headlines instantly.
Meanwhile, for British and European policymakers the implications are clear. Ageing populations and expensive biologics mean affordability pressures will intensify. Evidence from pharmaceutical competition research, including work by myself with my collaborators Lee Branstetter (Carnegie Mellon) and Matthew Higgins (Tulane University), shows durable savings arise when policy alters market-wide incentives rather than offering short-lived retail discounts. Structural procurement reform, credible generic substitution and competitive supply chains matter more than portals. This does not mean governments should retreat from intervention. Pharmaceutical markets require regulation because patents, information asymmetries and high development costs distort competition. But reform must focus on procurement design, competition policy and supply-chain governance.
In short, drug prices need policy beyond portals. TrumpRx and business history offers lessons here. America itself has done creative structural reforms such as the 1984 Hatch–Waxman Act, which research, including our own, shows generated substantial welfare gains through generic competition.
Overall TrumpRx marks a pivotal moment in the global politics and optics of medicines pricing. If pricing interventions spread without structural reform, governments risk substituting political theatre for sustainable solutions. Furthermore, this may come about by sacrificing the incentives for innovation in medicines. Political theatre may win elections, but societies and health of countries will suffer without structural reforms.
This article gives the views of the author, not the position of LSE Business Review or the London School of Economics. You are agreeing with our comment policy when you leave a comment.
Image credit: RomanR provided by Shutterstock.
